IBAT inhibitors for the treatment of liver diseases
The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
1. A method for treating a bile acid dependent disease in a subject, the method comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, wherein the IBAT inhibitor is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, or a pharmaceutically acceptable salt thereof, wherein the bile acid dependent disease is selected from the group consisting of Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), liver fibrosis, nonalcoholic fatty liver disease, non alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), intrahepatic cholestasis, extrahepatic cholestasis, a malignancy causing obstruction of the biliary tree, drug-induced cholestasis, cholestasis of pregnancy, and combinations thereof.
2. The method of claim 1 , wherein the IBAT inhibitor is administered in combination with ursodeoxycholic acid or nor-ursodeoxycholic acid.
3. The method of claim 1 , wherein the subject has pruritus as a symptom of the bile acid dependent disease.
4. The method of claim 1 , wherein the subject has pruritus as a comorbidity.
5. The method of claim 1 , wherein the bile acid dependent disease is selected from the group consisting of: Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), intrahepatic cholestasis, extrahepatic cholestasis, and combinations thereof.
6. The method of claim 1 , wherein the bile acid dependent disease is a malignancy causing obstruction of the biliary tree.
7. The method of claim 1 , wherein the bile acid dependent disease is intrahepatic cholestasis, extrahepatic cholestasis, or a combination thereof.
8. The method of claim 1 , wherein the concentration of serum bile acids in the subject is decreased following administration of the IBAT inhibitor.
9. The method of claim 1 , wherein the concentration of liver bile acids in the subject is decreased following administration of the IBAT inhibitor.
10. The method of claim 1 , wherein the subject is a pediatric subject.